PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 10, 2018 / MorphoSys AG (FSE: MOR) (XETRA: MOR) (OTC PINK: MPSYY) announced today that it has published its agenda for the Company's ordinary Annual General Meeting (AGM), which will take place on Thursday, May 17, 2018.
MorphoSys's Supervisory Board has nominated Dr. George Golumbeski and Michael Brosnan as candidates to be elected as new Supervisory Board members at the Company's AGM. Dr. Gerald Möller will retire from the board with the conclusion of the AGM 2018. Klaus Kühn has resigned from his Supervisory Board mandate for personal reasons, his resignation taking effect at the conclusion of the AGM 2018. Furthermore, the Supervisory Board will propose the re-election of Dr. Marc Cluzel, whose term of office would have expired with the conclusion of the AGM 2018.
"We are delighted that two highly qualified candidates with extensive industry expertise and leadership experience are standing for election to the MorphoSys Supervisory Board," said Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. "Dr. Golumbeski brings to our Board significant experience in corporate and business development in the global biopharmaceutical industry, particularly in the United States. Mr. Brosnan contributes his vast experience in finance and executive management of large multinational enterprises specifically in the healthcare industry and will contribute his knowledge as a qualified financial expert to MorphoSys," Dr. Möller added."On behalf of the Company, I would like to thank Mr. Kühn for his invaluable support and contribution to MorphoSys over the last three years."
"On behalf of the Supervisory Board, I would like to thank Dr. Möller, who will retire from the Supervisory Board at the end of the AGM 2018, for his great commitment and invaluable support over all these years," said Dr. Frank Morich, Deputy Chairman of the Supervisory Board of MorphoSys AG.
"Since he was elected to the Supervisory Board in 1999, Dr. Möller has played an essential role in helping us build and grow the Company to where we are now. On behalf of the Management Board and my fellow employees, I would like to thank him for everything he has done for MorphoSys. We sincerely wish him the happiest of futures," said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
Dr. Golumbeski currently serves as Executive Vice President & Executive Advisor for Innovation at Celgene Corporation, Summit, NJ, USA. He will retire from this position on April 16, 2018. Over the last 27 years, he has held leadership roles in business and corporate development, partnering and M&A with global pharmaceutical and life science companies, including Celgene, Novartis, Elan Corporation (today: Perrigo), and Schwarz Pharma (today: UCB). Dr. Golumbeski obtained his doctorate in genetics from the University of Wisconsin in Madison, USA and holds a degree in biology from the University of Virginia, Charlottesville, USA.
Mr. Brosnan has over 40 years of experience in finance, controlling and auditing. Since 2010, he has served as Chief Financial Officer of Fresenius Medical Care Management AG, Bad Homburg, Germany, a company with a dual listing in Germany (Frankfurt) and the United States (NYSE). Over the last 20 years, he has worked in various leadership and executive positions for Fresenius Medical Care in the United States and Germany. Prior to joining Fresenius Medical Care, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG. Mr. Brosnan holds a degree in business administration and accounting from Northeastern University, Boston, MA, USA.
About MorphoSys
MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on its technological leadership in generating antibodies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. This broad pipeline spans MorphoSys's two business segments: Proprietary Development, in which the Company invests in product candidates for its own account, and Partnered Discovery, in which product candidates are developed exclusively for our a variety of Pharma and Biotech partners. In 2017, Tremfya(R) (guselkumab), marketed by Janssen, became the first therapeutic antibody based on MorphoSys's proprietary technology to receive marketing approval for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union, and Canada. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Alexandra Goller
Associate Director Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Dr. Claudia Gutjahr-Loeser
Investor Relations Officer
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
SOURCE: MorphoSys AG
